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Hemeoxygenase(HO),acatabolicenzyme, providestherate-limitingstepintheoxidativebreakdownofheme,togeneratecarbon
monoxide (CO), iron, and biliverdin-IXα. Induction of the inducible form, HO-1, in tissues is generally regarded as a protective
mechanism. Over the last decade, considerable progress has been made in deﬁning the therapeutic potential of HO-1 in a number
of preclinical models of lung tissue injury and disease. Likewise, tissue-protective eﬀects of CO, when applied at low concentration,
have been observed in many of these models. Recent studies have expanded this concept to include chemical CO-releasing
molecules (CORMs). Collectively, salutary eﬀects of the HO-1/CO system have been demonstrated in lung inﬂammation/acute
lung injury, lung and vascular transplantation, sepsis, and pulmonary hypertension models. The beneﬁcial eﬀects of HO-1/CO are
conveyed in part through the inhibition or modulation of inﬂammatory, apoptotic, and proliferative processes. Recent advances,
however, suggest that the regulation of autophagy and the preservation of mitochondrial homeostasis may serve as additional
candidate mechanisms. Further preclinical and clinical trials are needed to ascertain the therapeutic potential of HO-1/CO in
human clinical disease.
1.Introduction
Stress-inducible protein systems represent a common and
ubiquitous strategy that eukaryotic cells and tissues employ
to maintain cellular homeostasis in adverse environments.
Of these, the heat shock proteins (HSPs), whose synthesis
increases with heat stress, and whose accumulation in turn
confers survival advantage to cells undergoing heat stress,
were among the ﬁrst to be identiﬁed [1–3]. HSPs act
as protein chaperones which play multifunctional roles in
protein traﬃcking and in the clearance of denatured protein
aggregates [3]. Although not strictly heat inducible in all
cell types, the increased expression of a low-molecular-
weight stress protein (32–34kDa) has emerged as a general
response to chemical and physical stress in cultured cells [4–
6]. Although the agents that induce this response belong to
seeminglydisparatechemicalandphysicalclasses,acommon
feature is their potential to evoke cellular oxidative stress
(i.e., altered redox homeostasis), and/or to stimulate the
inﬂammatory response [4–10]. The 32–34kDa protein was
identiﬁed as identical to heme oxygenase-1 [4], (HO, E.C.
1.14.99.3), a catabolic enzyme, which provides the rate-
limitingstepintheoxidativebreakdownofheme.Inthepres-
ence of O2 and the electron donor, NADPH: cytochrome p-
450 reductase, HO converts heme to biliverdin-IXα,w h i c hi s
then converted to bilirubin-IXα by biliverdin reductase [11]
(Figure 1). Additionally, ferrous iron and carbon monoxide
(CO) are released during heme degradation [11].
The lung represents a critical organ for toxicological
studies, since it provides essential life-sustaining functions
in the transfer of molecular oxygen (O2) to the circulatory
system for ultimate use in respiration and energy generation,
and at the same time can act as a major portal of entry for
xenobiotic and pathogen exposure [12]. The expression of2 International Journal of Hypertension
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Figure 1: The heme oxygenase reaction. Heme oxygenase-1 catalyzes the rate-limiting step in heme degradation. The reaction produces
biliverdin-IXα, carbon monoxide (CO), and ferrous iron (Fe II), at the expense of molecular oxygen and NADPH. Biliverdin-IXα produced
in the HO reaction is then converted to bilirubin-IXα by biliverdin reductase. (Side chains are labeled as M: methyl, V: vinyl, P: propionate).
The reactants and products of these enzymatic reactions have numerous and diverse biological sequelae. Heme is a vital molecule used
in biosynthesis of cytochromes and other hemoproteins. Accumulation of this metabolite may promote deleterious oxidative reactions.
Biliverdin-IXα and bilirubin-IXα may serve as cellular antioxidants, whereas circulating bilirubin may also provide antioxidant beneﬁt
in plasma. Bilirubin-IXα is conjugated by hepatic glucuronyltransferases and secreted by the biliary fecal route. CO has numerous signal
transduction eﬀects as outlined in this review. Systemic CO forms bind hemoglobin to form carboxyhemoglobin (CO-Hb). CO eventually
diﬀuses to the lung where it is eliminated as exhaled CO (eCO). Fe (II) represents a potentially toxic metabolite of heme degradation. A
potential metabolic fate of the released iron is sequestration by the iron storage protein ferritin.
HO-1 is now believed to act as a general protective mecha-
nismof thelunginresponse tostressstimuli, especiallythose
involving oxidative or inﬂammatory components [13–16].
HO-1 has in recent years been demonstrated to confer
protection in a number of preclinical animal models of tissue
injury and disease [13–20]( r e v i e w e di n[ 21]). This review
will highlight those aspects of HO-1 tissue protection rele-
vanttolung disease. Furthermore, accumulatingstudiesover
the past decade have shown that the exogenous application
of the HO-1 end-product CO, when administered at low
concentrations, or alternatively, by pharmacological applica-
tionofcarbon-releasingmolecules(CORMs),canalsoconfer
protective eﬀects in models of inﬂammatory stress or tissue
injury [22–24]( r e v i e w e di n[ 21, 25]). Tissue protection has
also been described for the exogenous application of bile
pigments,biliverdin-IXα,andbilirubin-IXα,whichrepresent
the end products of the heme degradation pathway [26–28].
Many of the studies concerning HO-1/CO-dependent
cytoprotection cite mechanisms involve the modulation of
the inﬂammatory response, including, but not limited to,International Journal of Hypertension 3
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Figure 2: Overview of the signaling pathways relevant to the cytoprotective eﬀects of CO. HO-1 and CO can confer cyto-/tissue-
protection in models of acute lung injury (ALI) and sepsis. The homeostatic and beneﬁcial eﬀects of CO gas and CO-releasing molecules
(CORMs) in animal models of ALI/sepsis occur through multiple cellular and molecular mechanisms that include regulation of the
redox state, inﬂammation, the vasodilation response. CO gas and CORMs regulate diﬀerent signaling pathways including cyclic guanosine
monophosphate (cGMP), mitogen-activated protein (MAP), kinase signaling pathways, and potassium (K+) ion channels. Autophagy is
regulated by HO-1/CO levels in a cell-type-speciﬁc manner and has a role in the maintenance of mitochondrial integrity and modulation of
reaction oxygen species (ROS) production.
downregulation of proinﬂammatory cytokine(s) production
[22, 23], as well as the modulation of programmed cell
death (i.e., apoptosis)[29, 30], and cell proliferation [31–34],
depending on cell type and experimental context (Figure 2).
More recent studies, as outlined in this review, suggest
additional novel candidate mechanisms for CO-dependent
protection, including the regulation of cellular macroau-
tophagy, the maintenance of mitochondrial integrity, and
mitochondrial biogenesis. This review will summarize recent
ﬁndings on the role of HO-1/CO in lung injury and pul-
monary disease, with an emphasis on disease pathogenesis
and potential therapeutic applications.
1.1. The Heme Oxygenase Enzyme System. The microsomal
enzyme heme oxygenase (HO, E.C. 1:14:99:3) exerts a
vital metabolic function in the regulation of cellular and
tissue heme homeostasis and consequently aﬀects intracel-
lular and tissue iron distribution [35]. The HO enzyme
was originally discovered (ca. 1968-1969) as an NADPH-
dependent enzymatic activity present in hepatic microso-
mal membrane preparations that is responsible for heme
degradation [11]. HO is distinct from cytochrome p450, the
major hepatic microsomal drug- and steroid-metabolizing
system [36]. The two systems share some common features,
including a requirement for electron mobilization from
the reductase component of cytochrome p450 [37–40].
Similartocytochromep450,theHOenzymereactionutilizes
an activated oxygen molecule (O2) bound to the ferrous
iron of a heme coenzyme to catalyze substrate oxidation
[38]. In contrast, p450 oxidizes a bound substrate (steroid
or xenobiotic compound) [37], whereas HO speciﬁcally
degrades heme [11,41,42].Theassociation ofhemewiththe
HO enzyme is transient, such that the bound heme uniquely
serves as both catalytic cofactor, and substrate [11, 41, 42].
HO catalyzes the selective ring opening of heme at the α-
methane bridge carbon to form the open chain tetrapyrrole
biliverdin-IXα. The reaction proceeds through three oxida-
tion cycles, requiring three moles of O2 per heme oxidized
[11, 43]. In each oxidation cycle, electrons from NADPH are
utilized to reduce the heme iron to the ferrous form, which
is permissive of O2 binding, and subsequently, to activate
the bound O2 [43]. For each molecule of heme oxidized,
one mole each of ferrous iron and carbon monoxide (CO)
are also released [11]. In catalyzing the breakdown of heme,
HO provides the major source of endogenous biological CO
production [11]. The HO reaction, which is rate limiting
for the pathway, is generally regarded as a detoxiﬁcation
reaction, in that heme, a potentially deleterious prooxidant4 International Journal of Hypertension
is processed for subsequent elimination steps. The cytosolic
enzyme, NAD(P)H: biliverdin reductase, reduces biliverdin-
IXα to the hydrophobic pigment bilirubin-IXα [44]. Biliru-
bin IXα accumulates in serum, where it circulates in a
protein-bound form, and acts as a physiological antioxidant
[45, 46]. Circulating bilirubin IXα is conjugated to water-
soluble glucuronide derivatives by hepatic microsomal phase
II enzymes and then subsequently eliminated through the
bile and feces [47].
1.2. HO Isozymes. HO can exist in two distinct isozymes:
the inducible form, heme oxygenase-1 (HO-1), and the
constitutively expressed isozyme, heme oxygenase-2 (HO-
2) [48]. The inducible isozyme HO-1 is a ubiquitous
mammalian shock protein (identiﬁed by molecular-cloning
strategies as identical to the major 32kDa mammalian stress
inducible protein) [4]. HO-1 is regulated at the transcrip-
tional level by environmental stress agents. The myriad of
inducing conditions that elicit this response is not limited
to xenobiotic exposure (i.e., heavy metals, sulfhydryl reactive
substances, oxidants) but also includes endogenous medi-
ators (i.e., prostaglandins, nitric oxide, cytokines, heme),
physical or mechanical stresses (i.e., shear stress, ultraviolet-
A radiation), and extremes in O2 availability (hyperoxia or
hypoxia), as reviewed in [21, 49]. The induction of HO-1
occurs as a general response to oxidative stress [4, 5, 50].
High levels of HO-1 expression occur in the spleen and
other tissues responsible in the degradation of senescent red
blood cells [11, 51]. With the exception of these tissues,
HO-1 expression is generally low in systemic tissues in the
absence of stress. Furthermore, the induction of HO-1 is
ac o m m o nr e s p o n s et oe l e v a t e dt e m p e r a t u r ei nr a to r g a n s
[52].
The constitutively expressed form, HO-2, is expressed
abundantly in the nervous and cardiovascular systems [16].
HO-2 catalyzes the identical biochemical reaction as HO-1
but represents a product of a distinct gene and diﬀers from
HO-1 in primary structure, molecular weight, and kinetic
parameters [53, 54]. HO-2 contains additional noncatalytic
heme-binding domains which are not present in HO-1
[55]. The transcriptional regulation of HO-2 is typically
refractory to most inducing agents with the exception of
glucocorticoids, which stimulate HO-2 transcription in the
nervous tissue [56, 57].
1.3. Heme Oxygenase-1: A Cytoprotective Molecule. It is now
well established in cell culture and animal studies that HO-
1 expression provides a general cyto- and tissue-protective
eﬀect, which is elicited as a generalized protective response
to environmental derangements. From published studies,
it is generally concluded that HO-1 can defend against
oxidative stress conditions in vitro and in vivo by modulating
apoptotic and inﬂammatory pathways [13, 18, 22, 58, 59].
However,the molecularprocessesand mechanisms,in which
HO-1 provides cellular and tissue protection, remain only
partially understood. The direct removal of heme may serve
an antioxidative function, since heme acts as a prooxidant
compound on the basis of its iron functional group [60, 61].
Hypothetically, a buildup of heme from the denaturation
of cellular hemoproteins, or from the impaired biosynthesis
or assembly of hemoproteins, may result in oxidative stress
to the cell, through the promotion of iron-dependent free
radical reactions (i.e., Fenton reaction). However, the extent
to which the “free” heme pool is mobilized during stress
remains unknown. Heme is well known as a lipid perox-
idation catalyst in model systems [60, 61]a n dm a yc a u s e
endothelial cell injury [62]. By breaking down heme, HO
liberates heme iron, which can itself represent a deleterious
catalytic byproduct with excessive overexpression [63]. HO-
derived iron has been shown to drive the synthesis of ferritin,
which serves as a protective sink for intracellular redox-
active iron [64]. In addition to iron, the reaction products
of the HO system, namely, biliverdin/bilirubin, and CO
may also contribute to cytoprotection. Evidence for this is
based largely on exogenous or pharmacological application
of CO or biliverdin/bilirubin as described in detail in the
sections below, and it remains incompletely clear whether
these mechanisms can account entirely for the cytoprotective
properties of the natural enzyme. An emerging consensus
is that the pleiotropic eﬀects of HO-1 summarized by the
collective eﬀects of the generation and distribution of bioac-
tive products and their downstream sequelae collectively
contribute to HO-dependent cytoprotection. In this regard,
HO-2 likely also serves as a protective agent against oxidative
stress by reducing intracellular heme concentrations and by
increasing levels of bilirubin and ferritin, both of which are
potent antioxidants [56]. However, HO-2 does not typically
respond to transcriptional activation via environmental
stimuli, although some posttranscriptional modulation of
expression has been described [57, 65].
T h ec r i t i c a lr o l eo fH O - 1i ns y s t e m i ch o m e o s t a s i sw a s
illustrated in the only documented case of HO-1 deﬁciency
inahumansubject,whopresentedwithextensiveendothelial
cell damage, anemia, and abnormal tissue iron accumulation
[66]. In addition, knockout mice with the Hmox1−/− geno-
type revealed hepatic and renal iron deposition, anemia and
increased vulnerability to oxidative stress [35, 67].
1.4.Biliverdin/BilirubinMediatorsofHO-DependentCytopro-
tection. T h ec y t o p r o t e c t i v ee ﬀects of HO-1 have been postu-
lated to involve the generation of its end products. The open-
chain tetrapyrroles biliverdin and bilirubin exert antioxidant
properties in vitro [45, 46], which have been demonstrated
to confer cytoprotective and antiproliferative properties [27,
28, 68, 69]( r e v i e w e di n[ 70, 71]). Increasing evidence
suggests that bilirubin plays an important physiological role
as an antioxidant in serum [38, 39]. Increases of serum BR
have been correlated with vascular protection and resistance
to oxidative stress in vivo [72]. Hyperbilirubinemic Gunn
rats display reduced plasma biomarkers of oxidative stress
following exposure to hyperoxia, relative to normal controls,
suggesting that hyperbilirubinemia may confer protection
against oxidative stress [72]. Recent clinical studies indicate
a relationship between circulating bilirubin levels and risk
of vascular disease. Serum BR levels were indicated as an
independent, inverse risk factor for coronary artery disease
and peripheral vascular disease [73, 74]. In a large-scale
prospective study of men, subjects in the midrange of serumInternational Journal of Hypertension 5
BR concentration were at the lowest incidence of ischemic
heart disease relative to those subjects displaying the lowest
or highest ﬁfth of serum BR distribution [75]. In healthy
subjects, serum BR levels were inversely correlated with two
indicators for atherosclerosis [76]. Patients with Gilbert’s
syndrome, who have increased levels of circulating unconju-
gatedbilirubinduetoreducedglucuronyltransferaseactivity,
displayed reduced incidence of ischemic heart disease when
compared to the general population [77]. Serum samples
from Gilbert’s patients were further shown to have increased
antioxidant capacity and resistance to oxidation [78]. It
should be noted that bilirubin also may exert toxicological
consequences at supraphysiological levels, as implicated in
the neurological injury associated with neonatal jaundice
[79].
2. ProtectiveEffects of HO-1/CO in
Lung Injury and Disease
2.1. HO-1/CO in Endotoxemia and Sepsis. HO-1, as an indu-
c i b l ec y t o p r o t e c t i v em o l e c u l e ,h a sb e e ni m p l i c a t e da sam o d -
ulator of the acute inﬂammatory response, as demonstrated
using in vitro and in vivo models of inﬂammatory stress [14,
15,22].HO-1geneexpressionviaadenovirus-mediated gene
delivery inhibited the bacterial lipopolysaccharide- (LPS-)
induced production of pro-inﬂammatory cytokines, such
as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
interleukin-6(IL-6),andmacrophageinﬂammatoryprotein-
1β (MIP-1β)i nc u l t u r e dm a c r o p h a g e sin vitro, and increased
the anti-inﬂammatory cytokine interleukin-10 (IL-10) levels
during LPS challenge [22].
HO-1 has also exhibited anti-inﬂammatory eﬀects
through in vivo models of inﬂammatory diseases. Additional
studies have shown that enhanced gene expression of HO-
1 in rat lungs via intratracheal adenoviral-mediated gene
transferlimitedmurineacutelunginjuryfollowinginﬂuenza
virus infection [14] and ameliorated LPS-induced lung
injury in mice via increased IL-10 production [15, 22].
Furthermore, administration of biliverdin, a direct product
of HO degradation, resulted in a signiﬁcant decrease of
proinﬂammatory cytokines, such as IL-6, upregulation of
IL-10 levels, and reduction of lung injury markers in LPS-
treated rats. Thus, biliverdin protected against systemic
inﬂammation and lung injury after lethal exposure to LPS.
This defense against LPS-induced injury applied to cultured
l u n ge n d o t h e l i a lc e l l sa sw e l la sm a c r o p h a g e s[ 80]. HO-1 has
also displayed anti-inﬂammatory eﬀects in various models
of tissue injury besides the lung, which include enhanced
protection during cardiac [81], renal [82], and liver [83]
transplantation.
Several recent studies have implicated a protective role
for HO-1 during microbial sepsis [84–87]. Using the cecal
ligation and puncture (CLP) technique to induce sepsis,
HO-1-deﬁcient mice (Hmox1−/−)s u ﬀered higher mortality
rates compared with HO-1 suﬃcient mice. These mice were
also shown to have an increased level of free circulating
heme rendering them more susceptible to death from sepsis
[85].
Conversely, targeted overexpression of HO-1 to smooth
muscle cells and myoﬁbroblasts, and bowel protected against
sepsis-inducedmortalityassociatedwithEnterococcusfaecalis
infection, enhanced bacterial clearance by increasing phago-
cytosis and the endogenous antimicrobial response [84].
High-mobility groupbox-1 (HMGB1)proteincanmedi-
ate various cellular responses, including chemotaxis and
accumulation of proinﬂammatory cytokines. Thus, this
molecule may represent a key target in strategies to limit
inﬂammation. With respect to potential mechanisms for
HO-1-mediated protection in sepsis, several studies have
demonstrated that circulating levels of HMGB1 contribute
to LPS-induced mortality in Hmox1−/− mice [86, 87].
Furthermore, the pharmacological administration of HO-
1-inducing compounds (i.e., heme) signiﬁcantly reduced
plasma levels of HMGB1 in mice challenged with LPS or
CLP, which was also associated with the reduction of serum
TNF-α,a n dI L - 1 β levels [86, 87]. Transfection of HO-1
or induction of HO-1-derived CO resulted in a signiﬁcant
reduction in the translocation and release of high-mobility
group box 1 (HMGB1) in CLP-induced sepsis in vivo.
In conclusion, HO-1-derived CO signiﬁcantly attenuated
HMGB1 release during sepsis, and this inhibition is a
necessary step of CO in protection against sepsis [87].
In vitro experiments showed that pretreatment with HO-
1 inducers, or transfection of HO-1, signiﬁcantly inhibited
HMGB1 release, translocation of HMGB1 from nucleus to
cytosol,andreleaseofproinﬂammatorycytokines(i.e.,TNF-
α,I L - 1 β,a n dI F N - β) in RAW264.7 cells stimulated with LPS.
These eﬀects were mimicked by CO donor compounds and
reversed by CO scavengers [87]. Thus, inhibition of HMGB1
release via HO-1 treatment may represent a potential
application for therapeutic intervention against sepsis [87].
Hemin administration was shown to protect mice from
lethal endotoxemia and sepsis induced by LPS or CLP,
respectively [87]. In this context, heme administration was
used as a pharmacological agent to induce HO-1 in healthy
animals before applying sepsis. In contrast however, a
recent study has suggested that heme-driven tissue damage
contributes to the pathogenesis of severe sepsis. The authors
demonstrate that the exacerbated mortality of Hmox1−/−
micesubjectedtolow-gradepolymicrobialinfectioninduced
by CLP correlated with the accumulation of free heme
in the plasma. Administration of free heme to wild-type
(Hmox1+/+) mice subjected to low-grade microbial infection
(nonlethal) was suﬃcient to elicit a lethal form of severe
sepsis. The development of lethal forms of severe sepsis
afterhigh-gradeinfectionwasassociatedwithreducedserum
concentrations of the heme-sequestering protein hemopexin
(HPX), a protein produced by the body to scavenge free
heme, whereas HPX administration after high-grade infec-
tionpreventedtissuedamageandlethality.Further,thelethal
outcome of septic shock in patients was associated with
reduced levels of serum HPX concentrations, suggesting that
targeting free heme by modulation of HPX might be used
therapeutically to treat severe sepsis. Therefore, in a clinical
setting, monitoring the patients’ levels of circulating heme
and/or HPX might be used to predict the likelihood of a fatal
o u t c o m ei ne a c hc a s eo fs e v e r es e p s i s[ 85].6 International Journal of Hypertension
COalsoplaysaroleintheprotectionagainstlunginﬂam-
mation and injury in rodents. In mice, low doses of CO
(250ppm), as well as HO-1 expression, when administered
with a sublethal dose of LPS, selectively inhibited the expres-
sion of LPS-induced proinﬂammatory cytokines including
TNFα,I L - 1 β,a n dM I P - 1 β [22]. CO dose-dependently
increased LPS-inducible IL-10 [22]. Similar eﬀects were
observed in cultured macrophages exposed to CO [22]. The
p38 mitogen-activated protein kinase (MAPK) pathway was
shown to be important for the CO-mediated eﬀect in these
cells [22].
The anti-inﬂammatory protection against LPS-induced
organ injury conferred by CO was also observed in asso-
ciation with inhibition of inducible nitric oxide synthase
(iNOS) expression and activity in the lung. In contrast,
while CO also protected against LPS-induced hepatic injury,
an enhancement of iNOS expression and activity by CO
was observed in this organ [88]. Studies of primary lung
macrophages and hepatocytes in vitro revealed a simi-
lar eﬀect; CO inhibited LPS-induced cytokine production
in lung macrophages while reducing LPS-induced iNOS
expression, and protected hepatocytes from apoptosis while
augmenting iNOS expression [88]. It remains unclear to
which extent these changes in iNOS contribute to the
cytoprotection conferred by CO, as it appears that the
functional consequences of iNOS regulation by CO diﬀer in
an organ-speciﬁc fashion.
Anti-inﬂammatory eﬀects of CO were also recently
demonstrated in a swine model of endotoxin challenge.
CO reduced the development of disseminated intravascular
coagulation and diminished serum levels of the proinﬂam-
matory IL-1β in response to LPS and induced IL-10 after
LPS challenge [89]. Recent studies evaluated the eﬃcacy of
inhaled CO in reducing LPS-induced lung inﬂammation in
cynomolgus macaques (a nonhuman primate model). CO
exposure (500ppm, 6h) following LPS inhalation decreased
TNF-α release in the bronchioalveolar lavage ﬂuid (BALF)
but did not aﬀect IL-6 and IL-8 release, in addition to
reducing pulmonary neutrophilia (not observed at lower
concentrations of CO). This reduction of pulmonary neu-
trophilia was as eﬃcacious as pretreatment with a well-
characterized inhaled corticosteroid. However, the therapeu-
tic eﬃcacy of CO required relatively high doses that resulted
in high carboxyhemoglobin (CO-Hb) levels (>30%). This
work highlights the complexity of interspecies variation of
dose-response relationships of CO to CO-Hb levels and to
the anti-inﬂammatory functions of CO [90]. This study is
the ﬁrst to examine the therapeutic index and dose-response
relationships of CO therapy in nonhuman primates, and this
warrants further investigations in humans [90].
2.2. HO-1/CO in High Oxygen Stress. O2 is required to sus-
tain aerobic life, but paradoxically, due to its biradical nature
and reactivity, and consequently its ability to participate in
electron transfer reactions, can also be harmful to life [91].
Supraphysiological concentrations of O2 (hyperoxia) are
routinelyusedintheclinictopreventortreathypoxemiaand
acute respiratory failure [92]. However, prolonged exposure
to hyperoxia can result in tissue damage in many organs,
including lungs, and lead to the development of both acute
and chronic lung injury [92]. Hyperoxia-induced damage
in mice is characterized by an alveolar-capillary barrier dys-
function, impaired gas exchange, and pulmonary edema [13,
93]. Elevated HO-1 protein expression was reported in lungs
of mice and in cultured epithelial cells subjected to hyperoxia
[93]. The expression of ho-1 in rat lungs by intratracheal
adenoviral-mediated gene transfer, which increased HO-1
expression in the bronchiolar epithelium, protected against
the development of pulmonary damage during hyperoxia
exposure [13]. Rats infected with ho-1 prior to hyperoxia
displayed reductions in lung injury markers, neutrophil
inﬁltration, and apoptosis, and a marked increase in survival
against hyperoxic stress when compared to control-infected
rats [13]. In vitro, HO-1 overexpression also protected
epithelial cells against hyperoxia-induced cytotoxicity [58].
Similarly, low doses of CO have been shown to provide
protection against hyperoxic lung injury. The administration
of CO (250ppm) during hyperoxia exposure prolonged
the survival of rats and mice subjected to a lethal dose
of hyperoxia and dramatically reduced histological indices
of lung injury, including airway neutrophil inﬁltration,
ﬁbrin deposition, alveolar proteinosis, pulmonary edema,
and apoptosis, relative to animals exposed to hyperoxia
alone [23, 94]. In mice, hyperoxia was shown to induce the
expression of proinﬂammatory cytokines (i.e., TNFα,I L - 1 β,
IL-6) and activate major MAPK pathways in lung tissue. The
protectionaﬀordedbyCOtreatmentagainstthelethaleﬀects
of hyperoxia correlated with the inhibited release of pro-
inﬂammatory cytokines in BALF. Genetic studies in mice
revealed that the anti-inﬂammatory eﬀect of CO depended
on the MKK3/p38β MAPK pathway [94]. Corresponding in
vitro studies of oxidative lung cell injury have also indicated
protective eﬀects of low-dose CO application (250ppm). CO
inhibited hyperoxia-induced apoptosis of cultured epithelial
cells, which required the activation of the MKK3/p38β
MAPK pathway [94]a sw e l la st h eS T A T 3p a t h w a y[ 95].
Further mechanistic studies in pulmonary endothelial cells
revealed that low-dose CO application inhibited the initi-
ation and propagation of extrinsic apoptotic pathways in
mouse lung endothelial cells subjected to hyperoxia [96]. CO
inhibited O2-induced activation of the death inducing signal
complex (DISC) and downstream activation of apoptogenic
factors, including caspases (−8, −9, −3) and Bid, thereby
aﬀording protection against cell death. CO also diminished
membrane-dependent reactive oxygen species (ROS) pro-
duction during hyperoxia by inhibiting the ERK1/2 MAPK
pathway [96].
2.3.HO-1/COinVentilator-InducedLungInjury. Mechanical
ventilation is commonly used clinically for the maintenance
of critically ill patients. However, this therapeutic tool can
lead to the development of acute lung injury (ALI)/and acute
respiratory distress syndrome (ARDS). Despite reductions
in tidal volume currently implemented during mechanical
ventilation in the clinic, the complications of ALI/ARDS
continue to present a high rate of mortality (∼40%) [97,
98]. The lung damage incurred by mechanical ventilation
is referred to as ventilator-induced lung injury (VILI) andInternational Journal of Hypertension 7
involves a sterile inﬂammatory response to cyclic stretching
of the tissue [99]. An anti-inﬂammatory eﬀect of CO was
ﬁrst described in a two-hit model of VILI in which rats
were subjected to an injurious high tidal volume ventilator
setting combined with intraperitoneal endotoxin injection.
This model caused increased expression of HO-1 in the
lung. The inclusion of low-concentration CO (250ppm) in
the ventilator circuit reduced the inﬂammatory cell count
in BALF. In the absence of cardiovascular derangements,
CO dose-dependently decreased TNFα and increased IL-
10 content in the BALF [100]. CO application was also
found to confer tissue protection in a mouse model of
VILI, using moderate tidal volume settings [101, 102].
In the mouse model, mechanical ventilation caused lung
injury reﬂected by increases in protein concentration, and
total cell and neutrophil counts in the BALF. CO reduced
ventilation-induced cytokine and chemokine production
and prevented lung injury during ventilation, as reﬂected
by the inhibition of ventilation-induced increases in BALF
protein concentration and cell count, lung neutrophil inﬂux,
and pulmonary edema formation [101, 102]. CO also
prevented the HO-1 response to mechanical ventilation,
indicating a tissue-protective eﬀect that preceded and did
not necessarily depend on secondary activation of stress
proteins [101]. Inclusion of CO during ventilation increased
the expression of the tumor-suppressor protein caveolin-
1 in mouse lung epithelium. Mice genetically deﬁcient in
caveolin-1 (Cav-1−/−) were reported to be more susceptible
to VILI than their wild-type counterparts. Furthermore, CO
ventilation failed to confer protection against mechanical
ventilation-induced lung injury in cav-1−/− mice, indicating
a requirement for caveolin-1 in the protective eﬀects of CO
[101]. Mechanical ventilation was also shown to increase the
expression of the proinﬂammatory transcriptional regulator
early growth response protein-1 (Egr-1) in the lungs of mice,
which in turn was inhibited by CO ventilation. The Egr-1−/−
mice resisted lung injury during ventilation, relative to
their wild-type counterparts, aﬃrming that Egr-1 acts as a
proinﬂammatory mediator in VILI [102].
In lung macrophages, peroxisome proliferator acti-
vated receptor-γ (PPAR-γ), a nuclear regulator, has been
demonstrated to act as an anti-inﬂammatory mediator by
counteracting the proinﬂammatory eﬀects of Egr-1 [103].
CO exposure was found to increase PPAR-γ in cultured
macrophages. Furthermore, chemical inhibition of PPAR-
γ in vivo reversed the protective eﬀects of CO in this model
with respect to Egr-1 regulation and lung injury parameters
[102]. These studies in VILI models are supportive of
general protective eﬀects of CO in the maintenance of the
alveolar-capillary barrier. CO has also been demonstrated
to inhibit alveolar ﬂuid clearance [104], and these eﬀects
should also be further studied when implementing CO for
pulmonary therapies. These studies collectively suggest that
mechanical ventilation in the presence of CO may provide
protection in animal models of VILI. Further research is
needed to better understand the pathogenesis of VILI as
well as the protective potential of CO and other so-called
therapeuticgasesinthesemodels.Itremainsunclearwhether
the protective eﬀects of these gases as observed in the
mouse would ultimately translate to clinical eﬀectiveness in
humans.
2.4. HO-1/CO in Pulmonary Ischemia Reperfusion Injury
and Lung Transplantation. The therapeutic potential of HO-
1/CO in ischemia/reperfusion (I/R) injury models has been
described extensively in rodent systems. Lung I/R caused by
occlusion of the pulmonary artery was shown to cause lung
apoptosis, as evidenced by biochemical markers including
caspase activation, expression changes in Bcl2 family pro-
teins, cleavage of PARP, and mitochondrial cytochrome-c
release [105]. CO conferred tissue protection in rodents sub-
jected to lung I/R injury, as evidenced by reduced markers of
apoptosis, which depended on activation of the MKK3/p38α
MAPK pathway [106]. Mechanistic studies from the same
laboratory revealed that CO conferred similar antiapoptotic
protection in cultured pulmonary artery endothelial cells
against anoxia reoxygenation stress, which was dependent
on activation of the MKK3/p38α MAPK pathway [106, 107].
Additional proposed pathway mechanisms included the
activation of the phosphatidylinositol-3-kinase/Akt pathway
and downstream induction of the signal transducer and
activator of transcription (STAT)-3 [107].
In vivo studies using homozygous ho-1 knockout mice
(hmox-1−/−) demonstrated that HO-1 deﬁciency conferred
sensitivity to the lethal eﬀects of lung I/R injury. Application
of exogenous CO by inhalation compensated for the HO-
1 deﬁciency in hmox-1−/− mice and improved survival
subsequenttopulmonaryI/R[108].Theprotectionprovided
by CO involved the stimulation of ﬁbrinolysis, by the cGMP-
dependent inhibition of plasminogen activator inhibitor-
1, a macrophage-derived activator of smooth muscle cell
proliferation [108]. CO also inhibited ﬁbrin deposition
and improved circulation in ischemic lungs [109]. These
protective eﬀects were related to the inhibited expression
of the proinﬂammatory transcription factor Egr-1, and the
subsequent downregulation of Egr-1 target genes, which
contribute to inﬂammatory or prothrombotic processes. The
downregulation of Egr-1 depended on the enhancement of
cGMP signaling by CO treatment, leading to the inhibition
of the ERK1/2 MAPK pathway [109].
I/R injury also represents an important causative com-
ponent of graft rejection after lung transplantation. During
orthotopic left lung transplantation in rats, the transplanted
lungs were shown to develop severe intra-alveolar hem-
orrhage and intravascular coagulation. The application of
continuous CO exposure (500ppm) markedly preserved the
graft and reduced hemorrhage, ﬁbrosis, and thrombosis
after transplantation. Furthermore, CO inhibited lung cell
apoptosis and downregulated lung and proinﬂammatory
cytokine and growth factor production which were induced
during transplantation [110]. Additional studies revealed
that protection against I/R and inﬂammatory injury was
reduced in syngeneic rat orthotopic lung transplantation
by inhalation exposure to either the donor or the recipient
[111]. Delivery of CO to lung grafts by saturation of the
preservation media reduced I/R injury and inﬂammation in
syngeneic rat orthotopic lung transplantation [112].8 International Journal of Hypertension
2.5. Protective Role of CO in Vascular Injury. Ap r o t e c t i v e
role for CO in vascular injury has been reported. In this
study, inhaled CO prevented arteriosclerotic lesions that
occur following aorta transplantation in rodent models.
Exposure to a low level of CO (250ppm) for 1 hour
before injury was suﬃcient to suppress intimal hyperplasia
arising from balloon injury [32]. The protective eﬀect
of CO was associated with inhibition of graft leukocyte
inﬁltration/activation as well as with inhibition of smooth
muscle cell proliferation [32]. A more recent study has
shown that intravenous injection of CO-saturated saline
caused immediate vasodilation and increased blood ﬂow in
the hamster skin microcirculation, an eﬀect that lasted up
to 90mins [113]. These changes were related to increased
cardiac output and local cGMP levels. This study supports
the possible use of CO-saturated solutions as a vasodilator
in critical conditions; however, dosage appears to be critical,
since higher and lower dosages by a factor of two were
ineﬀective [113].
2.6. Carbon Monoxide and Pulmonary Arterial Hyperten-
sion (PAH). Pulmonary arterial hypertension (PAH) is a
terminal disease characterized by a progressive increase in
pulmonary vascular resistance leading to right ventricular
failure. Several studies suggest that HO-1 or CO can exert
protective eﬀects in the context of pulmonary hyperten-
sion, and reverse hypoxic pulmonary vasoconstriction. The
hmox-1−/− null mice displayed an exaggerated response to
chronic hypoxia relative to wild-type mice, as exempliﬁed
by marked right heart hypertrophy, which included right
ventricular infarcts and the formation of mural thrombi
[114]. Chemical induction of HO-1 inhibited the develop-
ment of PAH in rat lungs in response to chronic hypoxia
[17]. Furthermore, transgenic mice with lung-speciﬁc over-
expression of HO-1 displayed reduced lung inﬂammation,
pulmonary hypertension, and vascular hypertrophy during
chronic-hypoxia treatment, relative to wild-type mice [18].
In monocrotaline- (MCT-) induced hypertension, protective
eﬀects were observed by treatment with the antiproliferative
agent rapamcyin, which were associated with the induction
of HO-1 [115]. In vitro, the antiproliferative eﬀect of
rapamycin on smooth muscle cells also depended in part
on HO-1 expression, as it was diminished in smooth muscle
cells derived from ho-1−/− mice [115].
Inhalation of CO has been shown to attenuate the
development of hypoxia-induced PAH in rats, by a mech-
anism possibly involving activation of Ca2+ -activated K+
channels [116] and NO generation [34]. In hypoxia and
monocrotaline-induced PAH in rodents, daily CO exposure
(250ppm, 1h) reversed established PAH and right ventric-
ular hypertrophy and restored right ventricular and pul-
monaryarterialpressures.COtreatmentrestoredpulmonary
vascular architecture to a near-normal condition [34]. The
protective eﬀect of CO was endothelial cell dependent and
associated with increased apoptosis and decreased cellular
proliferation of vascular smooth muscle cells [34]. The
ability of CO to reverse PAH was further shown to require
endothelial nitric oxide synthase (eNOS) and NO produc-
tion, as indicated by the inability of CO to reverse chronic
hypoxia-induced PAH in eNOS−/− mice [34]. Biliverdin and
bilirubin have also been shown to exert antiproliferative
eﬀects on vascular smooth muscle and thus may also have
therapeutic potential in PAH and other diseases involving
aberrant vascular cell proliferation [27, 28].
3. Role of HO-1/CO in the Regulation
of Autophagy
In addition to classical mechanisms such as apoptosis and
inﬂammation, several recent intriguing studies suggest that
HO-1, and its byproduct CO, can possibly impact the
regulationofautophagy,avitalcellularprocess,whichmayin
part contribute to the cytoprotective mechanism. Macroau-
tophagy (autophagy) is a regulated cellular pathway for the
turnover of organelles and proteins by lysosomal-dependent
processing. The autophagy mechanism involves double-
membrane vesicles, called autophagosomes or autophagic
vacuoles, that target and engulf cytosolic material, which
may include damaged organelles or denatured proteins.
The autophagosomes fuse with lysosomes to form single-
membrane autolysosomes. Lysosomal enzymes facilitate
a degradation process to regenerate metabolic precursor
molecules (i.e., amino acids, fatty acids), which can be
used for anabolic pathways and ATP production [117–
124]. This process may thereby prolong cellular survival
during starvation. During infection, autophagy assists in
the immune response by providing a mechanism for the
intracellular degradation of invading pathogens, such as
bacteria, and may also contribute to adaptive immune
mechanisms [123]. At least 30 autophagy-related (Atg)g e n e s
have been determined, primarily in yeast. The homologues
of many of these Atg genes have been shown to participate
in the regulation of autophagy [125, 126]. Among these,
Beclin 1 (the mammalian homolog of yeast Atg6) represents
a major autophagic regulator [126]. Beclin 1 associates
with a macromolecular complex that includes the class III
phosphatidylinositol-3 kinase (Vps34). The Beclin 1 com-
plex produces phosphatidylinositol-3-phosphate, a second
messenger that regulates autophagosomal nucleation [124,
125]. The microtubule-associated protein-1 light chain-3B
(LC3B), the mammalian homologue of Atg8 is an important
mediator of autophagosome formation, which is found in
association with the autophagosomal membrane [127].
Autophagy has been shown to be both protective and
injurious in a variety of diﬀerent models, suggesting that its
role in human diseases is complex. Autophagy is generally
considered to be protective when it is induced in response
to stress, reducing the activation of lethal signal transduction
cascades, and maintaining crucial levels of ATP that allow for
the generation of proteins and other biosynthetic reactions.
Autophagy also facilitates the elimination of potentially
toxic protein aggregates, helping to limit the accumulation
of ubiquitinylated proteins that otherwise would inhibit
proteasome function. Induction of autophagy aﬀects the
progression of the cell cycle (and vice versa), suggesting
that autophagy can inﬂuence cellular sensitivity to cell cycle-
dependent toxins [128].International Journal of Hypertension 9
Autophagy is rarely considered a suicidal mechanism as
it usually precedes apoptosis or necrosis [128]. Nevertheless,
autophagy has been proposed to contribute to Type-II
programmed cell death (PCD), a morphologically distinct
form of PCD that involves excess levels of cellular autophagy,
degradation of irreversibly damaged organelles, and preser-
vation of cytoskeletal elements. Autophagic cell death occurs
during development, in a number of homeostatic processes
in adulthood that require the elimination of large amounts
of cells, and during the neonatal period in order to maintain
cellular energy homeostasis and survival [129]. However,
thereisstillnoconclusiveevidencethataspeciﬁcmechanism
of autophagic cell death exists, as this phenomenon seems to
occur only in cells that cannot die by conventional apoptotic
mechanisms [130]. Apoptosis can occur at the same time as
autophagy in the same cells suggesting a common regulatory
mechanism; however, the precise crosstalk between these
two processes remains to be elucidated. Several proapoptotic
signaling molecules known to induce autophagy include
TRAIL [131], TNF [132], FADD, DRP-I (dynamin-related
protein-1), and DAPK (death-associated protein kinase)
[133]. Ca2+ is a major intracellular second messenger
involved in mediating both apoptosis and autophagy, where
elevated Ca2+ induces autophagy which can be inhibited by
ER-associatedBcl-2[134].TheBcl-2proteinsarealsoknown
to be important in both autophagy and apoptosis signaling.
Beclin 1 has been shown to interact with Bcl-2 resulting in
the inhibition of Beclin 1-mediated autophagy in response
to starvation [135, 136]. Further evidence for a cross-talk
between apoptosis and autophagy is also supported by a
recent study on Atg5. A truncated form of Atg5 (cleaved
by calpains 1 and 2) participates in apoptosis regulation
and translocates from the cytosol to mitochondria to trigger
cytochrome c release and caspase activation [134]. This Atg5
fragment has been shown to bind to Bcl-XL, displacing
Bcl-XL-Bax complexes, to inactivate Bcl-XL antiapoptotic
activity, thereby promoting Bax-Bax complex formation,
whichsuggeststhatAtg5maybeanindependentkeyplayerin
both apoptosis and autophagy. Functional mitochondria are
also needed for autophagic induction [137]. Mitochondria
have been proposed to act as a platform for controlling
the crosstalk between stress responses, autophagy, and
programmed cell death, however, the exact mechanisms
through which autophagy can intercept lethal signaling
remain unknown.
The role of autophagy, whether protective or deleterious,
in human diseases, or speciﬁcally in chronic lung disease
remains obscure. Recently, we demonstrated a pivotal role
for autophagy in cigarette smoke-induced apoptosis and
emphysema. We have observed increased autophagy in
mouse lungs subjected to chronic cigarette smoke exposure,
and in pulmonary epithelial cells exposed to cigarette smoke
extract (CSE). Knockdown of autophagic proteins inhibited
apoptosis in response to cigarette smoke exposure in vitro,
suggesting that increased autophagy was associated with
epithelial cell death. We have also observed increased mor-
phological and biochemical markers of autophagy in human
lungspecimensfrompatientswithchronicCOPD,suggestive
of novel therapeutic targets for COPD treatment [138].
HO-1 has been associated with both the cytoprotective
and cytotoxic functions of autophagy induction (Figure 3).
HO-1 induces a cytoprotective role for autophagy in lung
epithelial cells in response to cigarette smoke by downregu-
lating apoptosis and autophagy-related signaling [139]. CSE
increased the processing of LC3B-I to LC3B-II (the lipidated
active form), within 1hr of exposure in Beas-2B cells.
Increased LC3B-II was associated with increased autophagic
activity, since inhibitors of lysosomal proteases and of
autophagosome-lysosome fusion further increased LC3B-
II levels during CSE exposure. CSE concurrently induced
extrinsic apoptosis in Beas-2B cells involving early activation
of death-inducing-signaling-complex (DISC) formation and
downstream activation of caspases (−8, −9, −3). HO-
1 protected against such CSE-induced eﬀects; adenoviral-
mediated expression of HO-1 inhibited DISC formation
and caspase-3/9 activation in CSE-treated epithelial cells,
diminished the expression of Beclin 1, and partially inhibited
the processing of LC3B-I to LC3B-II. These studies were the
ﬁrst to demonstrate a relationship between autophagic and
apoptogenic signaling in CSE-induced cell death, and their
coordinated downregulation by HO-1 [139].
We have also shown that HO-1 mRNA expression was
elevated in the lungs of mice chronically exposed to cigarette
smoke [139], implying that HO-1 is upregulated in response
to cigarette smoke. In addition, HO-1 was shown to localise
to mitochondria in response to hemin, lipopolysaccharide,
and CSE in human alveolar (A549), or bronchial epithelial
cells (Beas-2B) [140]. These studies suggest that the intra-
cellular location of HO-1, in this case, translocation to the
mitochondria may be important for its role in remediating
cellular stress and cell death.
In other models, HO-1 has been shown to upregulate
autophagy in hepatocytes, leading to protection against
hepatocyte cell death and hepatic injury from infection-
induced sepsis in mice [141]. HO-1 and autophagy are
both upregulated in the liver in response to sepsis and LPS
and have been shown to limit cell death. Pharmacological
inhibition of HO-1 activity or knockdown of HO-1 prevents
the induction of autophagic signaling in this model and
resulted in increased hepatocellular injury, apoptosis, and
death [141]. Finally, HO-1 dependent autophagic signaling
has also been shown to have anti-inﬂammatory eﬀects in
LPS-stimulated macrophages where HO-1 and autophagy
collectively serve to limit cytokine production [142]. HO-
1 is integral to regulating and dampening the inﬂam-
matory response, as demonstrated by the expressed pro-
inﬂammatory phenotype found in HO-1 knockout mice.
Many of the anti-inﬂammatory eﬀects of HO-1 have been
attributed to CO which, when provided exogenously, is
known to decrease inﬂammation in macrophages and other
cells.
On the contrary, HO-1 has been shown to promote
autophagy and consequent cell death in a number of
models. HO-1 overexpression results in the activation of
mitochondrial-selective autophagy (mitophagy) resulting in
the accumulation of iron-laden cytoplasmic inclusions [143]
in Alzheimer’s disease and Parkinson’s disease. HO-1 has
also been implicated in the inhibition of autophagosome10 International Journal of Hypertension
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Figure 3: HO-1 as a regulator of autophagy. Autophagic machinery is mobilized in response to stress signals that result in mitochondrial
perturbationoraccumulationsofproteinaggregates.Anumberofproteinshavebeenidentiﬁedassignalingmoleculesinpreautophagosomal
assembly. These include master regulators such as the ULK1 complex, the Beclin-1/Vps34 complex, as well as the autophagic proteins LC3B
(Atg8), Atgs 5, 12, 16 which transiently associate with the nascent autophagosome. In inﬂammation models, HO-1 has been implicated as
an inducer of autophagy leading to cell survival and anti-inﬂammatory eﬀects. In this regard, HO-1 may preserve mitochondrial integrity
through the activation of mitochondrial-selective autophagy (mitophagy) which enhances cell survival. In models of neurodegeneration,
overexpression of HO-1 leading to activation of autophagy/mitophagy may be detrimental and contribute to neuronal cell death. In lung
epithelial cells, HO-1 prevents the induction of autophagy in response to cigarette smoke, leading to cell survival and inhibition of cell death
pathways. Overall, the role of HO-1 in controlling cell fate through autophagy is complex. In limited studies to date, the eﬀect of HO-1 on
autophagy varies in a cell-type and inducer-speciﬁc fashion.
formation in renal tubular epithelial cells exposed to
cisplatin promoting their survival. The absence of HO-
1 in renal epithelial cells treated with cisplatin results in
impaired autophagy and increased apoptosis. Restoring HO-
1 expression in these cells reversed the impaired autophagic
response and decreased susceptibility to cisplatin-induced
apoptosis, validating the importance of HO-1 expression
during cisplatin injury [144]. These data suggest that the
role of HO-1 in the control of autophagy is speciﬁc to
diﬀerences in stimulus and cell type; however, in general,
HO-1 induction and signaling is an adaptive response to
restore cellular homeostasis, much like autophagy. This
dual nature of autophagy and HO-1 and the increasing
number of pathologies they are associated with highlights
of the importance of studying the regulation and eﬀects of
autophagy and its control by HO-1 during lung injury.
Our recent studies suggest that CO exposure alone
has the potential to induce autophagy in epithelial cells.
CO treatment increased the expression and activation of
the autophagic protein LC3B in mouse lung, and in cul-
tured human alveolar or bronchial epithelial cells, in a
time-dependent manner [145]. Furthermore, CO exposure
elicited increased autophagosome formation in epithelial
cells, as determined by electron microscopy and GFP-
LC3 puncta assays. Recent studies indicate that ROS plays
an important role in the activation of autophagy. CO
upregulated mitochondria-speciﬁc generation of ROS in
epithelial cells. Furthermore, CO-dependent induction of
LC3B expression was inhibited by the general antioxi-
dant N-acetyl-L-cysteine and the mitochondria-targeting
antioxidant Mito-TEMPO, suggesting that CO promotes the
autophagic process through mitochondrial ROS generation.
We further examined the relationships between autophagic
proteins and CO-dependent cytoprotection, using a model
of hyperoxic stress. CO protected against hyperoxia-induced
cell death and inhibited hyperoxia-associated ROS produc-
tion. The ability of CO to protect against hyperoxia-induced
cell death and caspase-3 activation was compromised in
epithelial cells infected with LC3B-siRNA, indicating a role
for autophagic proteins [145]. These studies uncover a
potentially new candidate mechanism for the protective
action of CO in lung cells which has not been previously
explored. Further investigations are now underway to inves-
tigate elucidate the role of autophagy in lung disease and
injury, and in the therapeutic potential of HO-1/CO.
4.Pharmacological CO
4.1. Carbon-Monoxide-Releasing Molecules. The develop-
ment of transition metal-based carbon-monoxide-releasing
compounds (CORMs) has provided a pharmacological
method for delivery of CO as a promising alternative to
inhalation. The CORMs used in experimental studies to
date include Mn2CO10 (CORM-1) and the ruthenium-
basedcompoundstricarbonyldichlororuthenium-(II)-dimer
(CORM-2) and tricarbonylchoro(glycinato)-ruthenium (II)International Journal of Hypertension 11
(CORM-3) [146, 147]. CORM-1 and CORM-2 are soluble
in organic solvents, whereas CORM-3 dissolves in water and
rapidly releases CO in physiological ﬂuids. A nontransition
metallic water-soluble boron-containing CORM (CORM-
A1) has also been developed, which slowly releases CO
in a pH and temperature-dependent fashion (half-life of
21min) [148]. This chemical diﬀerence dictates how CO
causes vasorelaxation and hypotension as CORM-3 elicits
a prompt and rapid vasodilatory eﬀect, whereas CORM-
A1 promotes mild vasorelaxation and hypotension [149].
Recently, a novel light-sensitive CORM has been developed
[150]. Interestingly, and in contrast to inhaled CO, CORMs
appear to deliver CO directly to the tissues without sig-
niﬁcant formation of CO-Hb. There is an abundance of
preclinical evidence in large and small animals showing the
beneﬁcial eﬀects of CO, administered as a gas or as CORM,
incardiovasculardisease,sepsis,andshock;cancer,acuteand
chronicrejectionofatransplantedorgan;kidney,liverinjury,
and some published reports in the acute lung injury ﬁeld.
The chemistry of transition metals carbonyls is varied,
highly versatile, and not restricted to the above-described
compounds. Several subclasses of metal carbonyl com-
pounds containing either manganese, iron, cobalt, molyb-
denum, or ruthenium have been synthesized and tested for
their ability to act as CORMs [151]. Though the discovery of
these CORM compounds opens up new possibilities, there
are still several issues to overcome for medical applications,
particularly those in which downstream tissue sites draining
the injection site are targeted. These small molecular drugs
diﬀuse rapidly within the body after administration and
may liberate CO prior to reaching these target tissues.
Thus, there is considerable need for developing a safe and
eﬃcient CO-delivery system. Future work in this area should
be directed to the synthesis of CORMs which, beyond an
eﬀective therapeutic action and low toxicity, need molecular
characteristics with appropriate absorption, distribution,
metabolism, and excretion properties [25]. A recent report
by Kretschmer demonstrates the synthesis of a new CORM
(CORM-S1) based on iron and cysteamine, which is soluble
in water and releases CO under irradiation with visible light,
while it is widely stable in the dark [150]. This is the ﬁrst
example of a light-induced CO release from water-soluble
iron-basedCORMs,whichhaslowtoxicity,comparedtothat
of boron-containing compounds. Hubbell and colleagues
have developed micelle forms of metal carbonyl complexes
that displayed slowed diﬀu s i o ni nt i s s u e sa n db e t t e ra b i l i t y
to target distal tissue drainage sites [152]. The CO release
of the micelles was slower than that of CORM-3. CO-
releasing micelles eﬃciently attenuated the LPS-induced NF-
κB activation of human monocytes while CORM-3 did not
show any beneﬁcial eﬀects. This novel CO-delivery system
basedonCO-releasingmicellesmaybeusefulfortherapeutic
applications of CO. Eﬀorts in medicinal chemistry develop-
ment of metal carbonyl compounds are actively ongoing,
which should help establish these compounds as a new class
of drugs in the near future.
4.2. CORMs and Sepsis. CORM compounds are capable of
delivering small amounts of CO to biological systems in
a controlled manner and are emerging as a potential therapy
for sepsis. In terms of lung physiology, most studies to
date have focused on the therapeutic eﬀects of CORMs in
sepsis models. For example, CORMs reduce cytokine release
in LPS-stimulated macrophages [24] and decrease inﬂam-
matory response and oxidative stress in LPS-stimulated
endothelial cells [153]. In vivo, CORMs attenuate systemic
inﬂammation and proadhesive vascular cell properties in
septicandthermallyinjuredmicebyreducingnuclearfactor-
κB activation, protein expression of ICAM-1, and tissue
granulocyteinﬁltration[154,155].CORM-3hasbeenshown
topreventreoccurrenceofsepsis,CORM-2prolongssurvival
and reduces inﬂammation, while CORM-3 reduces liver
injury after CLP [155, 156]. These studies taken together
have demonstrated that the CORM-dependent release of CO
can reduce mortality in septic mice, suggesting that CORMs
could be used therapeutically to prevent organ dysfunction
and death in sepsis. As with inhaled CO, full consideration of
the toxicological and physiological properties of the released
CO, including possible eﬀects on hemodynamics, must
be understood before proceeding with CORMs as clinical
therapy, with additional considerations for the biological
properties of the chemical backbone and transition metal
components.
4.3. CORM and Ion Channels. Over the last decade, ion
channels have been recognized as important eﬀectors in
the actions of CO and may play roles in some of the
beneﬁcial eﬀects of CO. Members of several ion channel
families are molecular targets for the action of CO and/or
CORMsandinclude:(i)thelarge-conductance,voltage-,and
Ca2+-activated K+ channels [157–163]; (ii) the purinergic
P2X2 receptor [164]; (iii) the tandem P domain channel,
TREK1 [165]. Interestingly, CORM-2 inhibits the purinergic
P2X4 receptor [166]a n dK .2.1 [167]. Possible mechanisms
by which CO regulates ion channels may include sGC-
dependent signaling [168], direct binding of CO to the
polypeptide as proposed by Wang and Wu [157], indirect
bindingviaheme[161],ormodulationofcellularredoxstate
andmitochondrial function[167,169].Theprecisedetailsof
how CO diﬀerentially regulates each of these ion channels
is beginning to be elucidated but still warrants further
investigation and contradictory data has been reported for
each channel [170]. For example, the most widely studied
ion channel target of CO is the large-conductance, voltage-,
and Ca2+-activated K+ channel, BKCa. While a number of
mechanismshavebeenproposedtoexplainhowCOactivates
BKCa channels, the exact mechanism of action is unknown.
Direct binding of CO to extracellular histidines has been
reported [157] but mutagenesis of these residues did not
fully abolish the ability of CO to activate the ion channel
[160, 162]. CO has been proposed to bind to a high-aﬃnity,
channel-associated heme moiety on the α-subunit [160], yet
mutation of the key histidine residue required for heme
binding does not aﬀect CO activation of the channel [162].
Clearly, further investigation is required to determine the
exact mechanisms of action.
Two studies, with opposing outcomes, have reported
the regulation of voltage-activated, L-type Ca2+ channels.12 International Journal of Hypertension
A study by Scragg et al. demonstrated that CO, applied either
as the dissolved gas or from the donor molecule CORM-2,
inhibits both native (rat) and recombinant (human) cardiac
L-type Ca2+ channels [169]. This eﬀect arose due to the
ability of CO to bind to mitochondria, presumably by inter-
acting at complex IV causing electron leak speciﬁcally from
complexIII.SuchleakleadstorapidformationofROSwhich
causes channel inhibition through a speciﬁc interaction with
three cytosine residues in the C-terminal tail of the channel’s
major, pore-forming subunit. Therefore, CO evokes channel
modulation in the heart via production of mitochondrial
ROS [169]. In another study, the opposite results were
reported. Human recombinant intestinal smooth-muscle L-
type Ca2+ channels were shown to be activated by CO via
an NO-dependent mechanism [171]. The reasons for these
contrary observations remain unclear but may reﬂect tissue-
speciﬁc splice variation of L-type Ca2+ channels, as seen for
O2 regulation of L-type channels [172].
In conclusion, CO modulates ion channels via multiple
mechanisms, and it is hoped that these pathways and
targets may be exploited for therapeutic intervention in the
treatment of a number of important and diverse clinical
conditions.
4.4. CORM-3 and Mitochondrial Dynamics. The notion that
mitochondria serve as important targets in transducing the
beneﬁcial signaling properties of CO has been proposed
[173]. Recent studies indicate that increased mitochondrial
biogenesis is part of the mechanisms by which CO gas
and CORMs exert protective eﬀects against cardiomyopathy
and cardiac dysfunction in sepsis [174, 175]. Studies by
Lancel et al. investigated the potential of CORMs to preserve
mitochondrial function in the CLP model of sepsis. CORM-
3 treatment in CLP-induced mice prevented the decline
in mitochondrial function. Administration of CORM-3
during sepsis also stimulated mitochondrial biogenesis
with corresponding increases in (PPAR-γ-) coactivator-1α
protein expression and mitochondrial DNA copy num-
ber. CLP was found to impair mitochondrial energetic
metabolism and reduce mitochondrial biogenesis in mice
[175].
Recent work by Iacono et al. shows that low-micromolar
concentrations of CO, delivered to isolated heart mitochon-
dria by the water-soluble CORM-3, uncouple mitochondrial
respiration, consequently modulating both ROS produc-
tion and bioenergetic parameters. In addition, CORM-3
decreased mitochondrial membrane potential at concen-
trations that did not inhibit cytochrome c oxidase [176].
The CO-mediated eﬀects were attenuated by pharmaco-
logical agents known to inhibit mitochondrial uncoupling.
Taken together, this work demonstrates that CORM-3,
through the liberation of CO, represents a novel regulator
of mitochondrial respiration, which in addition to fatty
acids and thyroid and steroid hormones could play a
crucial role in those pathological conditions for which
strategies aimed at targeting mitochondrial uncoupling
and metabolism are developed for therapeutic interven-
tions.
5.ClinicalAspectsof CO
Studies have shown that CO exerts direct anti-inﬂammatory
eﬀects after LPS challenge in vitro a n di na nin vivo mouse
model [22]. Mice exposed to 250ppm CO for 1 hour before
LPS administration responded with signiﬁcantly lower levels
of proinﬂammatory cytokines (TNFα and IL-1β)a n dh i g h e r
levels of IL-10 than control mice. As a consequence of this
work, the role of CO in various rodent models has since been
investigated (reviewed in [25]). On the basis of the rationale
provided by these animal studies, Mayr and colleagues stud-
ied the eﬀects of CO inhalation on systemic inﬂammation
during experimental human endotoxemia. Speciﬁcally, in a
randomized, double-blinded, placebo-controlled, two-way
crossover trial, experimental endotoxemia was induced in
healthy volunteers by injection of 2ng/kgLPS. The potential
anti-inﬂammatory eﬀects of CO inhalation were investigated
by inhalation of 500ppm CO (leading to an increase in CO-
Hbfrom1.2%to7%)versussyntheticairasaplacebofor1h.
CO inhalation had no eﬀect on the inﬂammatory response
as measured by systemic cytokine production (TNF-α,I L -
6, IL-8, IL-1α,a n dI L - 1 β). In this study, no adverse side
eﬀectsofCOinhalationwereobserved[177].However,given
the limited scope of this initial trial, and the protective
characteristics of CO application in many animal models
of sepsis, further more detailed clinical trials are urgently
needed to reach a verdict on the eﬃcacy of CO for reducing
inﬂammation in septic patients. In contrast, a recent clinical
trial demonstrates the feasibility of administering inhaled
CO to humans with chronic obstructive pulmonary disease
(COPD) [178]. In this study, exsmoking patients with stable
COPD were subjected to CO inhalation (100–125ppm for
2 hours/day for 4 days), which increased CO-Hb levels to
4.5%. Inhalation of CO by patients with stable COPD led to
trends in reduction of sputum eosinophils and improvement
of methacholine responsiveness [178]. In summary, the
protective phenotype of CO in rodents in protecting against
lung disease has not been recapitulated in human trial
studies to date. One possibility is that diﬀerences in lung
physiologicalresponsestoCOexistbetweendiﬀerentspecies.
Further experiments are required to conﬁrm the safety and
eﬃcacy of CO inhalation as a treatment for inﬂammatory
lung diseases.
6. FinalRemarks
The overexpression of HO-1 by gene transfer has now been
shown to confer protection in several models of lung and
vascular injury and disease, as well as systemic inﬂammatory
diseases (i.e., sepsis). Potential clinical application of HO-
1 would imply targeted gene delivery or pharmacological
manipulation of gene expression [179]. The development of
vectors for tissue-speciﬁc delivery of HO-1 in humans may
facilitate gene therapy approaches [179].
Likewise,similarprotectiveeﬀectshavebeenreportedfor
inhalation CO in models of acute lung injury and sepsis.
T h ed e m o n s t r a t e dp r o t e c t i v ep r o p e r t i e so fl o w - d o s eC Oi n
preclinical rodent models continue to suggest promising
therapeutic applications for CO (reviewed in [21, 25, 180]).International Journal of Hypertension 13
More recent studies imply the stabilization of mitochondrial
function and the stimulation of cellular autophagy as
potential candidate mechanisms.
It should be noted that there are limitations, such that
some studies have been disputed, and some negative ﬁndings
reported [181, 182]. However, experimental work showing
therapeutic potential of CO has now been extended to large
animal models such as swine and nonhuman primates [89,
90].
As an alternative to inhalation of CO, pharmacological
application of CO using CORMs may provide a promising
therapeutic strategy [25]. Targeted delivery of CORMs may
reduce the systemic eﬀects associated with inhaled CO,
resulting from CO-Hb elevation, while retaining therapeutic
potential. Whether direct application of CO by CORMs
administration or inhalation will provide a safe and eﬀective
modality for the treatment of human disease requires further
researchdirectedatunderstandingthepharmacokineticsand
toxicology of CO or CORMs application in humans [25].
Ultimately, the goal of this experimentation remains to
translate the therapeutic potential of CO, whether inhaled
or administered through prodrugs, to possible medicinal
application in human disease. Although some obstacles
remain, limited human experimentation is now underway.
Pilot clinical trials to date have indicated either negative
eﬃcacy for human CO therapy in endotoxemia or partial
eﬃcacy in COPD, while several other trials involving organ
transplantation await completion [177, 178]. Currently,
new clinical studies in ﬁbrosis and sepsis are projected
to begin shortly. Despite the success in animal models,
which do not always directly translate to human disease, the
therapeutic beneﬁt of CO therapies has yet to be validated in
humans.
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